查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2106278

下一代藥物偶聯物市場（第二版）：按藥物偶聯物類型、靶向配體、有效載荷、給藥途徑、治療方法、治療領域和地區分類的趨勢和銷售預測（至 2035 年）

Next Generation Drug Conjugates Market (2nd Edition) by Type of Drug Conjugate, Targeting Ligand, Payload, Route of Administration, Type of Therapy, Therapeutic Area, Geographical Regions, and Sales Forecast - Trends and Forecast, Till 2035
出版日期: | 出版商: Roots Analysis | 英文 266 Pages | 商品交期: 最快1-2個工作天內

價格

下一代藥物偶聯物市場概述

根據 Roots Analysis 的研究，預計下一代藥物偶聯物的全球市場規模將從今年的 112 億美元成長到 2035 年的 262 億美元，在預測期內（到 2035 年）的複合年成長率為 9.9%。

下一代藥物偶聯物市場：成長與趨勢

新一代藥物偶聯物（XDCs）利用多種活性成分、連接子技術和標靶化機制，能夠將治療藥物精準遞送至病變組織，同時最大限度地降低靶外毒性。先進化學工程技術、創新設計方法和高特異性標靶化模式的引入，顯著提高了治療係數和療效，從而能夠開發出更精細的特異性治療方案。

新一代藥物偶聯物市場正迅速擴張，這主要得益於有效載荷技術（如寡核苷酸、胜肽和小分子）的不斷進步，以及連接子設計和偶聯平台方面的創新，這些創新增強了分子穩定性並實現了藥物的控釋。然而，儘管技術取得了這些進步，但有效載荷與靶點的兼容性、生產規模化以及物理化學複雜性等挑戰仍然存在，阻礙了其更廣泛的應用和商業化。

受腫瘤、罕見疾病和免疫介導疾病領域XDC應用範圍不斷擴大，以及精準醫療和多方位治療方法投資增加的推動，市場成長動能預計將持續。因此，新一代藥物偶聯物作為整個偶聯療法市場中一個極具前景和變革性的領域，正吸引越來越多的關注。

下一代藥物偶聯物市場-IMG1

下一代藥物偶聯物市場的細分

市場規模和機會分析根據以下參數進行分類：

藥物複合物類型

  • 配體介導的RNAi複合物
  • 配體結合反義藥物
  • 胜肽-放射性核種複合物
  • 小分子藥物偶聯物
  • 病毒樣藥物偶聯物
  • 放射性藥物複合物

透過標靶配體

  • 氨基糖
  • 胜肽
  • 脂質
  • 類病毒顆粒
  • 其他

有效載荷

  • siRNA
  • 放射性核種
  • 反義寡核苷酸
  • 藥物
  • 其他

透過行政途徑

  • 皮下
  • 靜脈
  • 向脈絡膜上腔給藥
  • 其他

治療類型

  • 單藥治療
  • 聯合治療
  • 其他

按治療區域

  • 遺傳性疾病
  • 腫瘤性疾病
  • 代謝性疾病
  • 心血管疾病
  • 自體免疫疾病
  • 血液疾病
  • 腎臟疾病
  • 肝病

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
  • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 澳洲
    • 亞太其他地區
  • 世界其他地區
    • 巴西
    • 阿根廷
    • 沙烏地阿拉伯

下一代藥物偶聯物市場：關鍵細分市場分析

配體介導的RNAi複合物正在推動癌症治療的發展。

配體介導的RNAi複合物目前佔約55%的市場佔有率，處於領先地位。這種主導地位源自於人們對療效較佳、安全性較高的療法的日益成長的需求。

病毒樣藥物偶聯物具有很高的成長潛力

病毒樣藥物偶聯物預計在預測期內將以相對較高的複合年成長率成長，表明其具有巨大的成長潛力。這種成長歸功於它們能夠透過模擬天然病毒的細胞入侵途徑，有效地將治療性有效載荷遞送至細胞內。

皮下注射正在推動市場擴張。

市場預測顯示，皮下給藥目前佔所有給藥途徑市場收入的60%以上。這一主導地位得益於諸多因素，例如給藥簡便、患者依從性提高、減少對醫院手術的依賴、癌症患者數量不斷增加、精準癌症治療的進步以及研發投入的增加。

單藥治療仍是主流治療方法。

市場分析表明，目前約95%的新一代藥物偶聯物以單藥療法的形式使用，預計這一趨勢將持續下去。主要原因包括給藥方案簡便、毒性較低，以及適用於長期疾病管理和個人化治療。近期認證核可藥支持這一趨勢，包括GIVLAARI®（吉博西蘭）、OXLUMO®（魯馬西蘭）、Leqvio®（因克西蘭）、AMVUTTRA®（布特西蘭）、PLUVICTO®（鎦-177 比匹伏肽四氫西坦）和Illuccix® PSMA-1）。

北美正在引領市場趨勢。

預計到2035年，北美將成為最大的區域市場，佔下一代藥物偶聯物市場55%​​以上的佔有率。這一主導地位得益於強大的產學研合作、先進的複雜藥物偶聯物生產能力​​以及健全的智慧財產權體系。該地區核准的主要藥物偶聯物包括GIVLAARI®、DAWNZERA™、TRYNGOLZA®、WAINZUA和Lutathera，累計這些藥物在2025年的淨銷售額約為8億美元。

歐洲強勁成長前景

歐洲新一代藥物偶聯物市場預計在預測期內將以約14%的複合年成長率成長。這一成長得益於諾華、諾和諾德、阿斯特捷利康和拜耳等領先生物製藥公司在該地區的持續投入，這些公司不斷加強在該地區的創新和研發。

本報告考察了下一代藥物偶聯物的全球市場，提供了概述、背景、市場影響因素分析、市場規模趨勢和預測、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。

目錄

第1章 背景

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章摘要整理

  • 市場狀況
  • 市場趨勢
  • 市場預測與機會分析

第6章：引言

  • 章節概要
  • 下一代藥物偶聯物概述
  • 重大歷史事件
  • 下一代藥物偶聯物的結構
  • 生化交互作用與作用機制
  • 主要適應症
  • 下一代藥物偶聯物的優勢
  • 下一代藥物偶聯物面臨的挑戰
  • 前景

第7章 市場狀況

  • 調查方法和關鍵參數
  • 下一代藥物偶聯物：治療方案列表
  • 下一代藥物偶聯療法計畫：開發商概覽

第8章：公司簡介

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Geron
  • Ionis Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Stemline Therapeutics
  • Telix Pharmaceuticals

第9章：臨床試驗分析

  • 調查方法和關鍵參數
  • 下一代藥物偶聯物：臨床試驗分析

第10章 夥伴關係與合作

  • 調查方法和關鍵參數
  • 合作模式
  • 下一代藥物偶聯物：合作與夥伴關係

第11章：學術研究津貼分析

第12章：論文分析

第13章：藥物失敗分析

第14章：成功方案分析

  • 調查方法和關鍵參數
  • 評分標準
  • 成功協議分析
  • Harveyball 分析：基於關鍵參數對已通過核准的下一代藥物偶聯物進行評估

第15章：全球下一代藥物偶聯物市場

  • 章節概要
  • 關鍵假設和調查方法
  • 下一代藥物偶聯物市場：歷史趨勢與預測
  • 主要市場區隔

第16章 下一代藥物偶聯物市場：按藥物偶聯物類型分類

  • 下一代藥物偶聯物市場：按藥物偶聯物類型分類
    • 配體介導的RNAi複合物：過去趨勢與預測
    • 配體結合反義藥物：過去趨勢與預測
    • 胜肽-放射性核種複合物：過去趨勢與預測
    • 小分子藥物偶聯物：過去趨勢與預測
    • 病毒樣藥物偶聯物：過去趨勢與預測
    • 放射性藥物複合物：過去趨勢與預測

第17章 下一代藥物偶聯物市場：以標靶配體分類

  • 下一代藥物偶聯物市場：以標靶配體分類
    • 氨基糖：過去趨勢與預測
    • 胜肽類：過去趨勢與預測
    • 脂質：過去趨勢與預測
    • 類病毒顆粒：過去趨勢與預測
    • 其他：過往趨勢和預測

第18章 下一代藥物偶聯物市場：依有效載荷分類

  • 下一代藥物偶聯物市場：按有效載荷分類
    • siRNA：過去趨勢與預測
    • 放射性核種：過去趨勢與預測
    • 反義寡核苷酸：過去趨勢與預測
    • 醫藥產業：過往趨勢與預測
    • 其他：過往趨勢和預測

第19章 下一代藥物偶聯物市場：依給藥途徑分類

  • 下一代藥物偶聯物市場：依給藥途徑分類
    • 皮下給藥：過去趨勢與預測
    • 靜脈注射：過去趨勢與預測
    • 脈絡膜上腔：過去趨勢與預測
    • 其他：過往趨勢和預測

第20章 下一代藥物偶聯物市場：依治療類型分類

  • 下一代藥物偶聯物市場：按治療類型分類
    • 單藥療法：過往趨勢與預測
    • 聯合治療：過往趨勢與預測
    • 其他：過往趨勢和預測

第21章 下一代藥物偶聯物市場：依治療領域分類

  • 下一代藥物偶聯物市場：按治療領域分類
    • 遺傳疾病：過去趨勢與預測
    • 腫瘤相關疾病：先前趨勢與預測
    • 代謝性疾病：過去趨勢與預測
    • 心血管疾病：既往趨勢與預測
    • 自體免疫疾病：過去趨勢與預測
    • 血液疾病：歷史趨勢與預測
    • 腎臟疾病：過去趨勢與預測
    • 肝病：過去趨勢與預測

第22章 下一代藥物偶聯物市場：按地區分類

  • 下一代藥物偶聯物市場：按地區分類
    • 北美洲
    • 歐洲
      • 德國
      • 西班牙
      • 法國
      • 英國
      • 義大利
      • 其他
    • 亞太地區
      • 中國
      • 日本
      • 澳洲
      • 其他
    • 其他地區
      • 巴西
      • 阿根廷
      • 沙烏地阿拉伯

第23章 市場機會分析：北美

  • 按複合材料類型
  • 透過標靶配體
  • 有效載荷
  • 透過行政途徑
  • 治療類型
  • 按治療區域

第24章 市場機會分析：歐洲

  • 按複合材料類型
  • 透過標靶配體
  • 有效載荷
  • 透過行政途徑
  • 治療類型
  • 按治療區域

第25章 市場機會分析：亞太地區

  • 按複合材料類型
  • 透過標靶配體
  • 有效載荷
  • 透過行政途徑
  • 治療類型
  • 按治療區域

第26章 市場機會分析：其他地區

  • 按複合材料類型
  • 透過標靶配體
  • 有效載荷
  • 透過行政途徑
  • 治療類型
  • 按治療區域

第27章 下一代藥物偶聯物市場：銷售預測

  • AMVUTTRA(R)/丁基矽烷/ALN-TTRSC04/ALN-TTRSC02：銷售預測
  • AAA617/PLUVICTO：銷售預測
  • Leqvio®/Incrylane：銷售預測
  • ARO-APOC3/Prozasilane/REDEMPLO：銷售預測
  • Imeterstat：銷售預測
  • Qfitlia(TM)/Fitsilan：銷售預測
  • TRYNGOLZA(R)/Olesarsen：銷售預測
  • WAINZUA/ApronTersen：銷售預測
  • Illuccix® (68Ga-PSMA-11)：銷售預測
  • AAA601/Lutathera(R)：銷售預測
  • Gozellix(R)：銷售預測
  • DAWNZERA(TM)/Donida Lolsen：銷售預測
  • OXLUMO(R)/魯馬斯蘭：銷售預測
  • GIVLAARI(R)/Giboshiran：銷售預測
  • LNTH-2501/EVG-001：銷售預測
  • Perakalsen：銷售預測
  • Semdisiran：銷售預測
  • SAR-bis PSMA：銷售預測
  • RYZ-101：銷售預測
  • ARO-ANG3/Zodasilan：銷售預測
  • Bel-sar/AU-011：銷售預測
  • RBD7022/QLC7401：銷售預測

第28章 結論

第29章 高階主管洞察

第30章 附錄1：表格形式數據

第31章 附錄2：公司與組織列表

Product Code: RA100455

NEXT GENERATION DRUG CONJUGATES MARKET: OVERVIEW

As per Roots Analysis, the global next generation drug conjugates market is estimated to grow from USD 11.2 billion in the current year to USD 26.2 billion by 2035, at a CAGR of 9.9% during the forecast period, till 2035.

NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS

Next generation drug conjugates (XDCs) leverage diverse payloads, linker technologies, and targeting mechanisms to facilitate the precise delivery of therapeutic agents to diseased tissues while minimizing off-target toxicity. The incorporation of advanced chemical engineering techniques, innovative design approaches, and highly specific targeting modalities has significantly improved their therapeutic index and efficacy, enabling the development of more sophisticated, site-directed treatment options.

The next generation drug conjugates landscape is witnessing rapid expansion, supported by continuous advancements in payload technologies, including oligonucleotides, peptides, and small molecules, as well as innovations in linker design and conjugation platforms that enhance molecular stability and enable controlled drug release. However, despite these technological developments, challenges related to payload-target compatibility, manufacturing scalability, and physicochemical complexity continue to pose barriers to broader adoption and commercialization.

Growing application of XDCs across oncology, rare diseases, and immune-mediated disorders, coupled with increasing investments in precision medicine and multimodal therapeutic approaches, is expected to sustain market momentum. As a result, next generation drug conjugates are emerging as a highly promising and transformative segment within the broader conjugate therapeutics industry.

Growth Drivers: Strategic Enablers of Market Expansion

The next generation drug conjugates (XDCs) field is undergoing rapid evolution, driven by continuous advancements in targeting precision, payload innovation, and hybrid therapeutic design. Improvements in linker stability, payload potency, and targeted delivery technologies are enhancing the therapeutic index of XDCs, enabling more effective eradication of diseased cells while reducing off-target toxicity. At the same time, increasing interest in RNA-based therapeutics is accelerating innovation in oligonucleotide payloads, with developers focusing on improving molecular stability, intracellular delivery, and controlled-release capabilities to unlock new opportunities in precision gene regulation. Building on these advances, the emergence of hybrid XDCs that integrate multiple payload modalities, including small molecules, peptides, and oligonucleotides, is expanding the therapeutic potential of conjugate platforms. These next generation constructs can simultaneously address multiple disease pathways through dual- or multi-mechanism approaches, positioning XDCs as a transformative therapeutic class capable of overcoming the limitations of conventional monotherapies and addressing increasingly complex disease indications.

Market Challenges: Critical Barriers Impeding Progress

The next generation drug conjugates (XDCs) market continues to face several development and commercialization challenges despite ongoing technological advancements. A key obstacle is achieving optimal compatibility between payloads, linkers, and targeting moieties, as variations in biological targets and intracellular delivery pathways can impact therapeutic efficacy and safety. In addition, the increasing structural complexity of XDCs, particularly those incorporating novel payloads such as oligonucleotides, peptides, and multi-functional constructs, creates significant manufacturing and scalability challenges related to process consistency, quality control, and cost efficiency. Furthermore, the physicochemical complexity of these therapeutics can affect stability, formulation, and pharmacokinetic performance, while evolving regulatory requirements for emerging conjugate modalities often necessitate extensive characterization and validation efforts. Collectively, these factors can prolong development timelines, increase commercialization costs, and present barriers to the broader adoption of next generation drug conjugates.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS

The report delves into the current state of the next generation drug conjugates market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 320 XDCs (~270 unique therapies) are currently approved / being investigated across various stages of development for various indications; of these, close to 60% are under different phases of clinical trials.

Next Generation Drug Conjugates Market - IMG1

2. Most (40%) of the XDC therapy programs are classified as ligand-drug conjugates; of these, over 95% function through sequence-specific target binding, ensuring covalent stability and exclusive payload delivery to target cells.

3 Most of the trials (~30%) were registered in H2 2025; notably, more than 70% of the registered trials are currently recruiting potential candidates for investigating next generation drug conjugates for various indications.

4. The growing interest in this industry is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to next generation drug conjugates were inked in 2021 and 2024.

Next Generation Drug Conjugates Market - IMG2

5. Close to 70% of the grants related to next generation drug conjugates were allocated for non-small business innovative research / small business technology transfer research.

6. The rising number of scientific articles being published in next generation drug conjugates market is indicative of the substantial efforts being undertaken by various stakeholders active in this domain.

7. 60% of the next generation drug conjugates were discontinued in Phase II of clinical trials; further, more than 45% of the conjugates that have been discontinued till date were ligand mediated RNAi conjugates.

Next Generation Drug Conjugates Market - IMG1

8. The next generation drug conjugates market is likely to grow at an annualized rate (CAGR) of 9.9%, till 2035; notably, the ligand-mediated RNAi conjugates is anticipated to capture the majority share in the market by 2035.

9. Currently, majority of the market share is captured by the genetic disorders sub-segment; a substantial market share is expected to be captured by North America, by 2035.

Next Generation Drug Conjugates Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Drug Conjugate

  • Ligand Mediated RNAi Conjugates
  • Ligand Conjugated Antisense Medicines
  • Peptide-Radionuclide Conjugates
  • Small Molecule Drug Conjugates
  • Virus-like Drug Conjugates
  • Radioconjugates

By Type of Targeting Ligand

  • Amino Sugars
  • Peptides
  • Lipids
  • Virus-like Particles
  • Others

By Type of Payload

  • siRNAs
  • Radionuclides
  • Antisense Oligonucleotides
  • Drugs
  • Others

By Route of Administration

  • Subcutaneous
  • Intravenous
  • Suprachoroidal
  • Others

By Type of Therapy

  • Monotherapies
  • Combination Therapies
  • Others

By Therapeutic Area

  • Genetic Disorders
  • Oncological Disorders
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Autoimmune Disorders
  • Hematological Disorders
  • Renal Disorders
  • Hepatic Disorders

By Geographical Regions

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
  • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Rest of the World
    • Brazil
    • Argentina
    • Saudi Arabia

NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENT INSIGHTS

Ligand-Mediated RNAi Conjugates Driving Cancer Therapy Development

According to the next generation drug conjugates market forecast, ligand-mediated RNAi conjugates currently dominate the market with approximately 55% share, driven by increasing demand for therapies with enhanced efficacy and improved safety profiles.

Growth Potential of Virus-Like Drug Conjugates

Virus-like drug conjugates are projected to expand at a higher CAGR, indicating significant growth potential over the forecast period. This growth is attributed to their ability to mimic natural viral entry pathways, enabling highly efficient intracellular delivery of therapeutic payloads.

Subcutaneous Administration Driving Market Expansion

Based on market forecasts, subcutaneous administration accounts for more than 60% of current revenues across routes of administration. This dominance is supported by ease of administration, improved patient adherence, reduced reliance on hospital-based procedures, rising cancer prevalence, advancements in oncology precision medicine, and increasing R&D investments in the field.

Next Generation Drug Conjugate Monotherapies to Remain Dominant

According to market analysis, approximately 95% of next generation drug conjugates are currently prescribed as monotherapy, a trend expected to persist in the foreseeable future. This is primarily due to simplified dosing regimens, reduced toxicity, and suitability for long-term disease management and personalized treatment approaches. Recent approvals supporting this trend include GIVLAARI(R) (givosiran), OXLUMO(R) (lumasiran), Leqvio(R) (inclisiran), AMVUTTRA(R) (vutrisiran), PLUVICTO(R) (lutetium Lu 177 vipivotide tetraxetan), and Illuccix(R) (Ga-68 PSMA-11).

North America Dominating the Market Landscape

North America is expected to lead the next generation drug conjugates market, accounting for over 55% share by 2035. This dominance is driven by strong academia-industry collaborations, advanced manufacturing capabilities for complex conjugates, and a robust intellectual property framework. Notable approved XDCs in the region include GIVLAARI(R), DAWNZERA(TM), TRYNGOLZA(R), WAINZUA, and Lutathera, which generated approximately USD 0.8 billion in net sales in 2025.

Strong Growth Outlook for Europe

The European next generation drug conjugates market is projected to grow at a CAGR of approximately 14% over the forecast period. This growth is supported by the presence of leading biopharmaceutical companies such as Novartis, Novo Nordisk, AstraZeneca, and Bayer, which continue to strengthen innovation and development within the region.

Example Players in Next Generation Drug Conjugates Market

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Geron
  • Ionis Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Stemline Therapeutics
  • Telix Pharmaceuticals

Next Generation Drug Conjugates Market Experts

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of the following third-party discussions:

  • Doctor of Medicine, Large Organization, Canada, North America
  • Doctor of Medicine, PhD, Large Organization, Spain, Europe
  • Vice President of Biologics Engineering and Tumor-Targeted Delivery, Large Organization, Europe
  • Surgical Oncologist, Cancer Research Organization, Denver, North America
  • Doctor of Medicine, Cancer Research Organization, US, North America
  • Chief Executive Officer, Large Organization, UK, Europe

NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation drug conjugates market, focusing on key market segments, including [A] type of drug conjugate, [B] type of targeting ligand, [C] type of payload, [D] route of administration, [E] type of therapy, [F] therapeutic area, [G] geographical regions, and [H] sales forecast.
  • Market Landscape: A detailed assessment of the overall next generation drug conjugates drugs landscape, featuring information on several relevant parameters, such as [A] stage of development, [B] type of conjugate, [C] mechanism of action, [D] type of therapy, [E] route of administration, [F] target indication, [G] therapeutic area, [H] target patient population [I] year of establishment, [J] company size, [K] location of headquarters, and [L] most active players.
  • Company Profiles: In-depth profiles of key drug developers in the next generation drug conjugate market, focusing on [A] company overview, [B] financial information, [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
  • Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to next generation drug conjugates, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial phase, [D] trial status, [E] type of sponsor / collaborator, [F] patient gender, [G] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [H] leading industry and non-industry players (based on number of clinical trials) and [I] geography.
  • Partnerships and Collaborations: An analysis of partnerships and collaborations signed in the next generation drug conjugates market, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] therapeutic area, [D] most active players, and [E] regional analysis.
  • Academic Grants Analysis: A comprehensive academic grants analysis, based on several parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant and [G] most popular recipient organizations.
  • Publication Analysis: An insightful publication analysis, based on several parameters, such as [A] year of publication, [B] type of publication, [C] most active publishers, and [D] most popular journals.
  • Drug Failure Analysis: An insightful drug failure analysis, based on several parameters, such as [A] trial phase, [B] trial status, [C] reason for drug discontinuation, [D] study start year, [E] year of discontinuation, [F] type of molecule, and [G] route of administration.
  • Success Protocol Analysis: An insightful analysis of recently approved next generation drug conjugates, based on several relevant parameters, such as [A] dosing frequency, [B] drug exclusivity, [C] safety and efficacy, [D] geographical reach, [E] intra-class competition, [F] line of treatment, [G] prevalence, [H] price, [I] type of therapy, and [J] existing competition among developers.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • Which are the leading companies in the next generation drugs market?
  • Which region dominates the next generation drugs market?
  • What are the key trends observed in the next generation drugs market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by next generation drug developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

ADDITIONAL BENEFITS

  • Complementary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Landscape
  • 5.2. Executive Summary: Market Trends
  • 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Overview of Next Generation Drug Conjugates
  • 6.3. Key Historical Events
  • 6.4. Structure of Next Generation Drug Conjugates
  • 6.5. Biochemical Interaction and Mechanism of Action
  • 6.6. Key Target Indications
  • 6.7. Advantages of Next Generation Drug Conjugates
  • 6.8. Challenges Associated with Next Generation Drug Conjugates
  • 6.9. Future Perspective

7. MARKET LANDSCAPE

  • 7.1. Methodology and Key Parameters
  • 7.2. Next Generation Drug Conjugates: List of Therapy Programs
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Type of Conjugate
    • 7.2.3. Analysis by Mechanism of Action
    • 7.2.4. Analysis by Type of Therapy
    • 7.2.5. Analysis by Route of Administration
    • 7.2.6. Analysis by Target Indication
    • 7.2.7. Analysis by Therapeutic Area
    • 7.2.8. Analysis by Target Patient Population
  • 7.3. Next Generation Drug Conjugates Therapy Programs: Developer Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Most Active Players: Analysis by Number of Next Generation Drug Conjugates

8. COMPANY PROFILES

  • 8.1. Alnylam Pharmaceuticals
    • 8.1.1. Company Overview
    • 8.1.2. Management Team
    • 8.1.3. Drug Portfolio
    • 8.1.4. Key Initiatives
  • 8.2. Arrowhead Pharmaceuticals
  • 8.3. Geron
  • 8.4. Ionis Pharmaceuticals
  • 8.5. Novartis
  • 8.6. Novo Nordisk
  • 8.7. Stemline Therapeutics
  • 8.8. Telix Pharmaceuticals

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Methodology and Key Parameters
  • 9.2. Next Generation Drug Conjugates: Clinical Trial Analysis
    • 9.2.1. Analysis by Trial Registration Year
    • 9.2.2. Analysis by Trial Status
    • 9.2.3. Analysis by Trial Registration Year and Trial Status
    • 9.2.4. Analysis of Patient Enrolled by Trial Registration Year
    • 9.2.5. Analysis by Trial Phase
    • 9.2.6. Analysis of Patient Enrolled by Trial Phase
    • 9.2.7. Analysis by Type of Sponsor / Collaborator
    • 9.2.8. Analysis by Study Design
    • 9.2.9. Analysis by Target Patient Population
    • 9.2.10. Most Active Industry Players: Analysis by Number of Clinical Trials
    • 9.2.11. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
    • 9.2.12. Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
    • 9.2.13. Analysis by Trial Status and Geography
    • 9.2.14. Analysis of Patients Enrolled by Trial Status and Geography

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Methodology and Key Parameters
  • 10.2. Partnership Models
  • 10.3. Next Generation Drug Conjugates: Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Year and Type of Partnership
    • 10.3.4. Analysis by Therapeutic Area
    • 10.3.5. Most Active Players: Analysis by Number of Partnerships
    • 10.3.6. Analysis by Local and International Agreements
    • 10.3.7. Analysis by Intercontinental and Intracontinental Agreements

11. ACADEMIC GRANTS ANALYSIS

  • 11.1. Methodology and Key Parameters
  • 11.2. Next Generation Drug Conjugates: Academic Grants Analysis
    • 11.2.1. Analysis by Year of Grant Award
    • 11.2.2. Analysis by Amount Awarded
    • 11.2.3. Analysis by Funding Institute Center
    • 11.2.4. Analysis by Support Period
    • 11.2.5. Analysis by Funding Institute Center and Support Period
    • 11.2.6. Analysis by Type of Grant Application
    • 11.2.7. Analysis by Purpose of Grant
    • 11.2.8. Analysis by Activity Code
    • 11.2.9. Analysis by Study Section
    • 11.2.10. Popular NIH Departments: Analysis by Number of Grants
    • 11.2.11. Analysis by Type of Recipient Organization
      • 11.2.11.1. Most Popular Recipient Organizations: Analysis by Number of Grants
      • 11.2.11.2. Most Popular Recipient Organizations: Analysis by Amount Awarded
    • 11.2.12. Prominent Program Officers: Analysis by Number of Grants
    • 11.2.13. Analysis by Location of Recipient Organizations in the US

12. PUBLICATION ANALYSIS

  • 12.1. Methodology and Key Parameters
  • 12.2. Next Generation Drug Conjugates: Publication Analysis
    • 12.2.1. Analysis by Year of Publication
    • 12.2.2. Analysis by Type of Publication
    • 12.2.3. Analysis by Year and Type of Publication
    • 12.2.4. Most Active Publishers: Analysis by Number of Publications
    • 12.2.5. Most Popular Journals: Analysis by Number of Publications
    • 12.2.6. Most Popular Journals: Analysis by Impact Factor

13. DRUG FAILURE ANALYSIS

  • 13.1. Methodology and Key Parameters
  • 13.2. Next Generation Drug Conjugates: Drug Failure Analysis
    • 13.2.1. Analysis by Trial Phase
    • 13.2.2. Analysis by Trial Status
    • 13.2.3. Analysis by Reason for Drug Discontinuation
    • 13.2.4. Analysis by Study Start Year and Year of Discontinuation
    • 13.2.5. Analysis by Target Indication
    • 13.2.6. Analysis by Type of Conjugate
    • 13.2.7. Analysis by Type of Sponsor / Collaborator

14. SUCCESS PROTOCOL ANALYSIS

  • 14.1. Methodology and Key Parameters
  • 14.2. Scoring Criteria
  • 14.3. Success Protocol Analysis
  • 14.4. Harvey Ball Analysis: Assessment of Approved Next Generation Drug Conjugates across Key Parameters

15. GLOBAL NEXT GENERATION DRUG CONJUGATES MARKET

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 15.3.1. Scenario Analysis
      • 15.3.1.1. Conservative Scenario
      • 15.3.1.2. Optimistic Scenario
  • 15.4. Key Market Segmentations

16. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF CONJUGATE

  • 16.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate
    • 16.1.1. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 16.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 16.1.3. Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 16.1.4. Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 16.1.5. Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 16.1.6. Next Generation Drug Conjugates Market for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF TARGETING LIGAND

  • 17.1. Next Generation Drug Conjugates Market: Distribution by Type of Targeting Ligand
    • 17.1.1. Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 17.1.2. Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 17.1.3. Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 17.1.4. Next Generation Drug Conjugates Market for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 17.1.5. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF PAYLOAD

  • 18.1. Next Generation Drug Conjugates Market: Distribution by Type of Payload
    • 18.1.1. Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 18.1.2. Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 18.1.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 18.1.4. Next Generation Drug Conjugates Market for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 18.1.5. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19. NEXT GENERATION DRUG CONJUGATES MARKET, BY ROUTE OF ADMINISTRATION

  • 19.1. Next Generation Drug Conjugates Market: Distribution by Route of Administration
    • 19.1.1. Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 19.1.2. Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 19.1.3. Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 19.1.4. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF THERAPY

  • 20.1. Next Generation Drug Conjugates Market: Distribution by Type of Therapy
    • 20.1.1. Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 20.1.2. Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 20.1.3. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21. NEXT GENERATION DRUG CONJUGATES MARKET, BY THERAPEUTIC AREA

  • 21.1. Next Generation Drug Conjugates Market: Distribution by Therapeutic Area
    • 21.1.1. Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.2. Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.3. Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.4. Next Generation Drug Conjugates Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.5. Next Generation Drug Conjugates Market for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.6. Next Generation Drug Conjugates Market for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.7. Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.1.8. Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

22. NEXT GENERATION DRUG CONJUGATES MARKET, BY GEOGRAPHICAL REGIONS

  • 22.1. Next Generation Drug Conjugates Market: Distribution by Geographical Regions
    • 22.1.1. Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 22.1.1.1. Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 22.1.1.2. Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.2. Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.2.1. Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.2.2. Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.2.3. Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.2.4. Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.2.5. Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.2.6. Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.3. Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.1. Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.2. Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.3. Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.4. Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.4. Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.4.1. Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.4.2. Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.4.3. Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

  • 23.1 Next Generation Drug Conjugates Market in North America: Distribution by Type of Conjugate
    • 23.1.1. Next Generation Drug Conjugates Market in North America for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.1.2. Next Generation Drug Conjugates Market in North America for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.1.3. Next Generation Drug Conjugates Market in North America for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.1.4. Next Generation Drug Conjugates Market in North America for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.1.5. Next Generation Drug Conjugates Market in North America for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.1.6. Next Generation Drug Conjugates Market in North America for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.2. Next Generation Drug Conjugates Market in North America: Distribution by Type of Targeting Ligand
    • 23.2.1. Next Generation Drug Conjugates Market in North America for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.2.2. Next Generation Drug Conjugates Market in North America for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.2.3. Next Generation Drug Conjugates Market in North America for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.2.4. Next Generation Drug Conjugates Market in North America for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.2.5. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3. Next Generation Drug Conjugates Market in North America: Distribution by Type of Payload
    • 23.3.1. Next Generation Drug Conjugates Market in North America for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2. Next Generation Drug Conjugates Market in North America for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3. Next Generation Drug Conjugates Market in North America for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4. Next Generation Drug Conjugates Market in North America for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.5. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.4. Next Generation Drug Conjugates Market in North America: Distribution by Route of Administration
    • 23.4.1. Next Generation Drug Conjugates Market in North America for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.4.2. Next Generation Drug Conjugates Market in North America for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.4.3. Next Generation Drug Conjugates Market in North America for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.4.4. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.5. Next Generation Drug Conjugates Market in North America: Distribution by Type of Therapy
    • 23.5.1. Next Generation Drug Conjugates Market in North America for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.5.2. Next Generation Drug Conjugates Market in North America for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.5.3. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.6. Next Generation Drug Conjugates Market in North America: Distribution by Therapeutic Area
    • 23.6.1. Next Generation Drug Conjugates Market in North America for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.2. Next Generation Drug Conjugates Market in North America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.3. Next Generation Drug Conjugates Market in North America for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.4. Next Generation Drug Conjugates Market in North America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.5. Next Generation Drug Conjugates Market in North America for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.6. Next Generation Drug Conjugates Market in North America for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.7. Next Generation Drug Conjugates Market in North America for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.6.8. Next Generation Drug Conjugates Market in North America for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24. MARKET OPPORTUNITY ANALYSIS: EUROPE

  • 24.1 Next Generation Drug Conjugates Market in Europe: Distribution by Type of Conjugate
    • 24.1.1 Next Generation Drug Conjugates Market in Europe for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.1.2. Next Generation Drug Conjugates Market in Europe for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.1.3. Next Generation Drug Conjugates Market in Europe for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.1.4. Next Generation Drug Conjugates Market in Europe for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.1.5. Next Generation Drug Conjugates Market in Europe for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.1.6. Next Generation Drug Conjugates Market in Europe for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.2. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Targeting Ligand
    • 24.2.1. Next Generation Drug Conjugates Market in Europe for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.2.2. Next Generation Drug Conjugates Market in Europe for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.2.3. Next Generation Drug Conjugates Market in Europe for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.2.4. Next Generation Drug Conjugates Market in Europe for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.2.5. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Payload
    • 24.3.1. Next Generation Drug Conjugates Market in Europe for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.2. Next Generation Drug Conjugates Market in Europe for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.3. Next Generation Drug Conjugates Market in Europe for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.4. Next Generation Drug Conjugates Market in Europe for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.5. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.4. Next Generation Drug Conjugates Market in Europe: Distribution by Route of Administration
    • 24.4.1. Next Generation Drug Conjugates Market in Europe for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.4.2. Next Generation Drug Conjugates Market in Europe for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.4.3. Next Generation Drug Conjugates Market in Europe for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.4.4. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.5. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Therapy
    • 24.5.1. Next Generation Drug Conjugates Market in Europe for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.5.2. Next Generation Drug Conjugates Market in Europe for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.5.3. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.6. Next Generation Drug Conjugates Market in Europe: Distribution by Therapeutic Area
    • 24.6.1. Next Generation Drug Conjugates Market in Europe for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.2. Next Generation Drug Conjugates Market in Europe for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.3. Next Generation Drug Conjugates Market in Europe for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.4. Next Generation Drug Conjugates Market in Europe for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.5. Next Generation Drug Conjugates Market in Europe for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.6. Next Generation Drug Conjugates Market in Europe for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.7. Next Generation Drug Conjugates Market in Europe for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.6.8. Next Generation Drug Conjugates Market in Europe for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

  • 25.1 Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Conjugate
    • 25.1.1. Next Generation Drug Conjugates Market in Asia-Pacific for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.1.2. Next Generation Drug Conjugates Market in Asia-Pacific for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.1.3. Next Generation Drug Conjugates Market in Asia-Pacific for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.1.4. Next Generation Drug Conjugates Market in Asia-Pacific for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.1.5. Next Generation Drug Conjugates Market in Asia-Pacific for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.1.6. Next Generation Drug Conjugates Market in Asia-Pacific for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.2. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Targeting Ligand
    • 25.2.1. Next Generation Drug Conjugates Market in Asia-Pacific for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.2.2. Next Generation Drug Conjugates Market in Asia-Pacific for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.2.3. Next Generation Drug Conjugates Market in Asia-Pacific for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.2.4. Next Generation Drug Conjugates Market in Asia-Pacific for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.2.5. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Payload
    • 25.3.1. Next Generation Drug Conjugates Market in Asia-Pacific for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.2. Next Generation Drug Conjugates Market in Asia-Pacific for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.3. Next Generation Drug Conjugates Market in Asia-Pacific for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.4. Next Generation Drug Conjugates Market in Asia-Pacific for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.5. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.4. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Route of Administration
    • 25.4.1. Next Generation Drug Conjugates Market in Asia-Pacific for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.4.2. Next Generation Drug Conjugates Market in Asia-Pacific for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.4.3. Next Generation Drug Conjugates Market in Asia-Pacific for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.4.4. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.5. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Therapy
    • 25.5.1. Next Generation Drug Conjugates Market in Asia-Pacific for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.5.2. Next Generation Drug Conjugates Market in Asia-Pacific for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.5.3. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.6. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Therapeutic Area
    • 25.6.1. Next Generation Drug Conjugates Market in Asia-Pacific for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.2. Next Generation Drug Conjugates Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.3. Next Generation Drug Conjugates Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.4. Next Generation Drug Conjugates Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.5. Next Generation Drug Conjugates Market in Asia-Pacific for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.6. Next Generation Drug Conjugates Market in Asia-Pacific for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.7. Next Generation Drug Conjugates Market in Asia-Pacific for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.6.8. Next Generation Drug Conjugates Market in Asia-Pacific for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD

  • 26.1 Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Conjugate
    • 26.1.1. Next Generation Drug Conjugates Market in Rest of the World for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.1.2. Next Generation Drug Conjugates Market in Rest of the World for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.1.3. Next Generation Drug Conjugates Market in Rest of the World for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.1.4. Next Generation Drug Conjugates Market in Rest of the World for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.1.5. Next Generation Drug Conjugates Market in Rest of the World for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.1.6. Next Generation Drug Conjugates Market in Rest of the World for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.2. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Targeting Ligand
    • 26.2.1. Next Generation Drug Conjugates Market in Rest of the World for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.2.2. Next Generation Drug Conjugates Market in Rest of the World for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.2.3. Next Generation Drug Conjugates Market in Rest of the World for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.2.4. Next Generation Drug Conjugates Market in Rest of the World for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.2.5. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Payload
    • 26.3.1. Next Generation Drug Conjugates Market in Rest of the World for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.2. Next Generation Drug Conjugates Market in Rest of the World for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.3. Next Generation Drug Conjugates Market in Rest of the World for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.4. Next Generation Drug Conjugates Market in Rest of the World for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.5. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.4. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Route of Administration
    • 26.4.1. Next Generation Drug Conjugates Market in Rest of the World for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.4.2. Next Generation Drug Conjugates Market in Rest of the World for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.4.3. Next Generation Drug Conjugates Market in Rest of the World for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.4.4. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.5. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Therapy
    • 26.5.1. Next Generation Drug Conjugates Market in Rest of the World for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.5.2. Next Generation Drug Conjugates Market in Rest of the World for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.5.3. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.6. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Therapeutic Area
    • 26.6.1. Next Generation Drug Conjugates Market in Rest of the World for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.2. Next Generation Drug Conjugates Market in Rest of the World for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.3. Next Generation Drug Conjugates Market in Rest of the World for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.4. Next Generation Drug Conjugates Market in Rest of the World for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.5. Next Generation Drug Conjugates Market in Rest of the World for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.6. Next Generation Drug Conjugates Market in Rest of the World for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.7. Next Generation Drug Conjugates Market in Rest of the World for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.6.8. Next Generation Drug Conjugates Market in Rest of the World for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27. NEXT GENERATION DRUG CONJUGATES MARKET: SALES FORECAST

  • 27.1. AMVUTTRA(R) / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02: Sales Forecast (USD Million)
  • 27.2. AAA617 / PLUVICTO: Sales Forecast (USD Million)
  • 27.3. Leqvio(R) / inclisiran: Sales Forecast (USD Million)
  • 27.4. ARO-APOC3 / Plozasiran / REDEMPLO: Sales Forecast (USD Million)
  • 27.5. Imetelstat: Sales Forecast (USD Million)
  • 27.6. Qfitlia(TM) / Fitusiran: Sales Forecast (USD Million)
  • 27.7. TRYNGOLZA(R) / olezarsen: Sales Forecast (USD Million)
  • 27.8. WAINZUA / Eplontersen: Sales Forecast (USD Million)
  • 27.9. Illuccix(R) (68Ga-PSMA-11): Sales Forecast (USD Million)
  • 27.10. AAA601 / Lutathera(R): Sales Forecast (USD Million)
  • 27.11. Gozellix(R): Sales Forecast (USD Million)
  • 27.12. DAWNZERA(TM) / donidalorsen: Sales Forecast (USD Million)
  • 27.13. OXLUMO(R) / lumasiran: Sales Forecast (USD Million)
  • 27.14. GIVLAARI(R) / givosiran: Sales Forecast (USD Million)
  • 27.15. LNTH-2501 / EVG-001: Sales Forecast (USD Million)
  • 27.16. Pelacarsen: Sales Forecast (USD Million)
  • 27.17. Cemdisiran: Sales Forecast (USD Million)
  • 27.18. SAR-bis PSMA: Sales Forecast (USD Million)
  • 27.19. RYZ-101: Sales Forecast (USD Million)
  • 27.20. ARO-ANG3 / Zodasiran: Sales Forecast (USD Million)
  • 27.21. Bel-sar / AU-011: Sales Forecast (USD Million)
  • 27.22. RBD7022 / QLC7401: Sales Forecast (USD Million)

28. CONCLUDING INSIGHTS

29. EXECUTIVE INSIGHTS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 List of Next Generation Drug Conjugates Therapy Programs
  • Table 7.2 List of Next Generation Drug Conjugate Developers
  • Table 9.1 Next Generation Drug Conjugate Therapy Programs: List of Clinical Trials, (Since 2024)
  • Table 10.1 Next Generation Drug Conjugates Market: List of Partnerships and Collaborations, (Since 2018)
  • Table 11.1 Next Generation Drug Conjugates: List of Academic Grants, (Since 2018)
  • Table 12.1 Next Generation Drug Conjugates Market: List of Publications, (Since 2020)
  • Table 13.1 List of Discontinued Next Generation Drug Conjugates
  • Table 15.1 Next Generation Drug Conjugates Market, Till 2035
  • Table 25.1 Next Generation Drug Conjugate Therapy Programs: Distribution by Stage of Development
  • Table 25.2 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Conjugate
  • Table 25.3 Next Generation Drug Conjugate Therapy Programs: Distribution by Mechanism of Action
  • Table 25.4 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Therapy
  • Table 25.5 Next Generation Drug Conjugate Therapy Programs: Distribution by Route of Administration
  • Table 25.6 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Indication
  • Table 25.7 Next Generation Drug Conjugate Therapy Programs: Distribution by Therapeutic Area
  • Table 25.8 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Target Patient Population
  • Table 25.9 Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
  • Table 25.10 Next Generation Drug Conjugate Developers: Distribution by Company Size
  • Table 25.11 Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters
  • Table 25.12 Next Generation Drug Conjugate Developers: Most Active Players: Distribution by Number of Next Generation Drug Conjugates
  • Table 25.13 Clinical Trial Analysis: Analysis by Trial Registration Year (Since 2024)
  • Table 25.14 Clinical Trial Analysis: Analysis by Trial Status
  • Table 25.15 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status
  • Table 25.16 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year
  • Table 25.17 Clinical Trial Analysis: Analysis by Trial Phase
  • Table 25.18 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase
  • Table 25.19 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator
  • Table 25.20 Clinical Trial Analysis: Analysis by Study Design
  • Table 25.21 Clinical Trial Analysis: Analysis by Target Patient Population
  • Table 25.22 Clinical Trial Analysis: Most Active Industry Players: Analysis by Number of Clinical Trials
  • Table 25.23 Clinical Trial Analysis: Most Active Non-Industry Players: Analysis by Number of Clinical Trials
  • Table 25.24 Clinical Trial Analysis: Analysis by Number of Clinical Trials and Patient Enrolled
  • Table 25.25 Clinical Trial Analysis: Analysis by Number of Trials by Trial Status and Geography
  • Table 25.26 Clinical Trial Analysis: Analysis by Trial Status and Geography
  • Table 25.27 Clinical Trial Analysis: Analysis of Number of Patients Enrolled by Trial Status and Geography
  • Table 25.28 Partnerships and Collaborations: Analysis by Year of Partnership
  • Table 25.29 Partnerships and Collaborations: Analysis by Type of Partnership
  • Table 25.30 Partnerships and Collaborations: Analysis by Year and Type of Partnership
  • Table 25.31 Partnerships and Collaborations: Analysis by Therapeutic Area
  • Table 25.32 Partnerships and Collaborations: Most Active Players: Analysis by Number of Partnerships
  • Table 25.33 Partnerships and Collaborations: Analysis by Local and International Agreements
  • Table 25.34 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements
  • Table 25.35 Academic Grants Analysis: Analysis by Year of Grant Award
  • Table 25.36 Academic Grants Analysis: Analysis by Amount Awarded (USD Million)
  • Table 25.37 Academic Grants Analysis: Analysis by Funding Institute Center
  • Table 25.38 Academic Grants Analysis: Analysis by Support Period
  • Table 25.39 Academic Grants Analysis: Funding Institute Center and Support Period
  • Table 25.40 Academic Grants Analysis: Analysis by Type of Grant Application
  • Table 25.41 Academic Grants Analysis: Analysis by Purpose of Grant
  • Table 25.42 Academic Grants Analysis: Analysis by Activity Code
  • Table 25.43 Academic Grants Analysis: Analysis by Study Section
  • Table 25.44 Academic Grants Analysis: Most Popular NIH Departments: Analysis by Number of Grants
  • Table 25.45 Academic Grants Analysis: Type of Recipient Organization
  • Table 25.46 Academic Grants Analysis: Popular Recipient Organizations: Analysis by Number of Grants
  • Table 25.47 Academic Grants Analysis: Popular Recipient Organizations: Analysis by Amount Awarded (USD Million)
  • Table 25.48 Academic Grants Analysis: Prominent Program Officers: Analysis by Number of Grants
  • Table 25.49 Academic Grants Analysis: Prominent Program Officers: Location of Recipient Organizations in the US
  • Table 25.50 Publication Analysis: Analysis by Year of Publication, Since 2020
  • Table 25.51 Publication Analysis: Analysis by Type of Publication
  • Table 25.52 Publication Analysis: Analysis by Year and Type of Publication, Since 2020
  • Table 25.53 Most Active Publishers: Analysis by Number of Publications
  • Table 25.54 Most Popular Journals: Analysis by Number of Publications
  • Table 25.55 Most Popular Journals: Analysis by Impact Factor
  • Table 25.56 Drug Failure Analysis: Analysis by Trial Phase
  • Table 25.57 Drug Failure Analysis: Analysis by Trial Status
  • Table 25.58 Drug Failure Analysis: Analysis by Reason for Drug Discontinuation
  • Table 25.59 Drug Failure Analysis: Analysis by Study Start Year and Year of Discontinuation
  • Table 25.60 Drug Failure Analysis: Analysis by Target Indication
  • Table 25.61 Drug Failure Analysis: Analysis by Type of Conjugate
  • Table 25.62 Drug Failure Analysis: Analysis by Type of Sponsor / Collaborator
  • Table 25.63 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Scenario Analysis
  • Table 25.64 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative Scenario
  • Table 25.65 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Optimistic Scenario
  • Table 25.66 Global Next Generation Drug Conjugates Market, Analysis by Type of Conjugate
  • Table 25.67 Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.68 Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.69 Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.70 Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.71 Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Forecasted Estimates (Till 2035)
  • Table 25.72 Next Generation Drug Conjugates Market for Radioconjugates Forecasted Estimates (Till 2035)
  • Table 25.73 Global Next Generation Drug Conjugates Market, Analysis by Type of Targeting Ligand
  • Table 25.74 Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.75 Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.76 Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.77 Next Generation Drug Conjugates Market for Virus-like Particles, Forecasted Estimates (Till 2035)
  • Table 25.78 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2035)
  • Table 25.79 Global Next Generation Drug Conjugates Market, Analysis by Type of Payload
  • Table 25.80 Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.81 Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.82 Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.83 Next Generation Drug Conjugates Market for Drugs, Forecasted Estimates (Till 2035)
  • Table 25.84 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2035)
  • Table 25.85 Global Next Generation Drug Conjugates Market, Analysis by Route of Administration
  • Table 25.86 Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.87 Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.88 Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.89 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.90 Global Next Generation Drug Conjugates Market, Analysis by Type of Therapy
  • Table 25.91 Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2535)
  • Table 25.92 Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2535)
  • Table 25.93 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2535)
  • Table 25.94 Global Next Generation Drug Conjugates Market, Analysis by Therapeutic Area
  • Table 25.95 Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.96 Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.97 Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.98 Next Generation Drug Conjugates Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035)
  • Table 25.99 Next Generation Drug Conjugates Market for Autoimmune Disorders, Forecasted Estimates (Till 2035)
  • Table 25.100 Next Generation Drug Conjugates Market for Hematological Disorders, Forecasted Estimates (Till 2035)
  • Table 25.101 Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.102 Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.103 Global Next Generation Drug Conjugates Market, Analysis by Geographical Regions
  • Table 25.104 Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.105 Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.106 Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.107 Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.108 Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.109 Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.110 Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.111 Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.112 Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.113 Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.114 Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.115 Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.116 Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.117 Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.118 Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.119 Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.120 Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.121 Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.122 Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Table 25.123 Next Generation Drug Conjugate Market for AMVUTTRA(R) / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.124 Next Generation Drug Conjugates Market for AAA617 / PLUVICTO, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.125 Next Generation Drug Conjugates Market for Leqvio(R) / inclisiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.126 Next Generation Drug Conjugates Market for ARO-APOC3 / Plozasiran / REDEMPLO, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.127 Next Generation Drug Conjugates Market for Imetelstat, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.128 Next Generation Drug Conjugates Market for Qfitlia(TM) / Fitusiran, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.129 Next Generation Drug Conjugates Market for TRYNGOLZA(R) / olezarsen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.130 Next Generation Drug Conjugates Market for WAINZUA / Eplontersen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.131 Next Generation Drug Conjugates Market for Illuccix(R) (68Ga-PSMA-11), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.132 Next Generation Drug Conjugates Market for AAA601 / Lutathera(R), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.133 Next Generation Drug Conjugates Market for Gozellix(R), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.134 Next Generation Drug Conjugates Market for DAWNZERA(TM) / donidalorsen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.135 Next Generation Drug Conjugates Market for OXLUMO(R) / lumasiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.136 Next Generation Drug Conjugates Market for GIVLAARI(R) / givosiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.137 Next Generation Drug Conjugates Market for LNTH-2501 / EVG-001, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.138 Next Generation Drug Conjugates Market for Pelacarsen, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.139 Next Generation Drug Conjugates Market for Cemdisiran, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.140 Next Generation Drug Conjugates Market for SAR-bis PSMA, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.141 Next Generation Drug Conjugates Market for RYZ-101, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.142 Next Generation Drug Conjugates Market for ARO-ANG3 / Zodasiran, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.143 Next Generation Drug Conjugates Market for Bel-sar / AU-011, Forecasted Estimates (Till 2035) (USD Million)
  • Table 25.144 Next Generation Drug Conjugates Market for RBD7022 / QLC7401, Forecasted Estimates (Till 2035) (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 3.3 Market Dynamics: Example List of Parameters
  • Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 6.1 Structure of Next Generation Drug Conjugates
  • Figure 6.2 Biochemical Interaction and Mechanism of Action
  • Figure 7.1 Next Generation Drug Conjugate Therapy Programs: Distribution by Stage of Development
  • Figure 7.2 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Conjugate
  • Figure 7.3 Next Generation Drug Conjugate Therapy Programs: Distribution by Mechanism of Action
  • Figure 7.4 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Therapy
  • Figure 7.5 Next Generation Drug Conjugate Therapy Programs: Distribution by Route of Administration
  • Figure 7.6 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Indication
  • Figure 7.7 Next Generation Drug Conjugate Therapy Programs: Distribution by Therapeutic Area
  • Figure 7.8 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Patient Population
  • Figure 7.9 Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters
  • Figure 7.10 Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
  • Figure 7.11 Next Generation Drug Conjugate Developers: Distribution by Company Size
  • Figure 7.12 Most Active Players: Distribution by Number of Next Generation Drug Conjugates
  • Figure 9.1 Clinical Trial Analysis: Analysis by Trial Registration Year
  • Figure 9.2 Clinical Trial Analysis: Analysis by Trial Status
  • Figure 9.3 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status
  • Figure 9.4 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year
  • Figure 9.5 Clinical Trial Analysis: Analysis by Trial Phase
  • Figure 9.6 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase
  • Figure 9.7 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator
  • Figure 9.8 Clinical Trial Analysis: Analysis by Study Design
  • Figure 9.9 Clinical Trial Analysis: Analysis by Target Patient Population
  • Figure 9.10 Most Active Industry Players: Analysis by Number of Clinical Trials
  • Figure 9.11 Most Active Non- Industry Players: Analysis by Number of Clinical Trials
  • Figure 9.12 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
  • Figure 9.13 Clinical Trial Analysis: Analysis by Trial Status and Geography
  • Figure 9.14 Clinical Trial Analysis: Analysis of Patients Enrolled by Trial Status and Geography
  • Figure 10.1 Partnerships and Collaborations: Analysis by Year of Partnership
  • Figure 10.2 Partnerships and Collaborations: Analysis by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Analysis by Year and Type of Partnership
  • Figure 10.4 Partnerships and Collaborations: Analysis by Therapeutic Area
  • Figure 10.5 Most Active Players: Analysis by Number of Partnerships
  • Figure 10.6 Partnerships and Collaborations: Analysis by Local and International Agreements
  • Figure 10.7 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements
  • Figure 11.1 Academic Grants Analysis: Analysis by Year of Grant Award
  • Figure 11.2 Academic Grants Analysis: Analysis by Amount Awarded
  • Figure 11.3 Academic Grants Analysis: Analysis by Funding Institute Center
  • Figure 11.4 Academic Grants Analysis: Analysis by Support Period
  • Figure 11.5 Academic Grants Analysis: Analysis by Funding Institute Center and Support Period
  • Figure 11.6 Academic Grants Analysis: Analysis by Type of Grant Application
  • Figure 11.7 Academic Grants Analysis: Analysis by Purpose of Grant
  • Figure 11.8 Academic Grants Analysis: Analysis by Activity Code
  • Figure 11.9 Academic Grants Analysis: Analysis by Study Section
  • Figure 11.10 Popular NIH Departments: Analysis by Number of Grants
  • Figure 11.11 Academic Grants Analysis: Analysis by Type of Recipient Organization
  • Figure 11.12 Popular Recipient Organizations: Analysis by Number of Grants
  • Figure 11.13 Popular Recipient Organizations: Analysis by Amount Awarded (USD Million)
  • Figure 11.14 Prominent Program Officers: Analysis by Number of Grants
  • Figure 11.15 Academic Grants Analysis: Analysis by Location of Recipient Organization in the US
  • Figure 12.1 Publication Analysis: Analysis by Year of Publication
  • Figure 12.2 Publication Analysis: Analysis by Type of Publication
  • Figure 12.3 Publication Analysis: Analysis by Year and Type of Publication
  • Figure 12.4 Most Active Publishers: Analysis by Number of Publications
  • Figure 12.5 Most Popular Journals: Analysis by Number of Publications
  • Figure 12.6 Most Popular Journals: Analysis by Impact Factor
  • Figure 13.1 Drug Failure Analysis: Analysis by Trial Phase
  • Figure 13.2 Drug Failure Analysis: Analysis by Trial Status
  • Figure 13.3 Drug Failure Analysis: Analysis by Reason for Drug Discontinuation
  • Figure 13.4 Drug Failure Analysis: Analysis by Study Start Year and Year of Discontinuation
  • Figure 13.5 Drug Failure Analysis: Analysis by Target Indication
  • Figure 13.6 Drug Failure Analysis: Analysis by Type of Conjugate
  • Figure 13.7 Drug Failure Analysis: Analysis by Type of Sponsor / Collaborator
  • Figure 14.1 Success Protocol Analysis: Spider Web Analysis for Lutathera
  • Figure 14.2 Success Protocol Analysis: Spider Web Analysis for Pluvicto
  • Figure 14.3 Success Protocol Analysis: Spider Web Analysis for Givlaari
  • Figure 14.4 Success Protocol Analysis: Spider Web Analysis for Oxlumo
  • Figure 14.5 Success Protocol Analysis: Spider Web Analysis for Amvuttra
  • Figure 14.6 Success Protocol Analysis: Spider Web Analysis for Leqvio
  • Figure 14.7 Harvey Ball Analysis: Assessment of Approved Next Generation Drug Conjugates across Key Parameters
  • Figure 15.1 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Scenario Analysis
  • Figure 15.2 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative Scenario
  • Figure 15.3 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Optimistic Scenario
  • Figure 16.1 Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 16.2 Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 16.3 Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 16.4 Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 16.5 Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 16.6 Next Generation Drug Conjugates Market for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 17.1 Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 17.2 Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 17.3 Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 17.4 Next Generation Drug Conjugates Market for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 17.5 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 18.1 Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 18.2 Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 18.3 Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 18.4 Next Generation Drug Conjugates Market for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 18.5 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 19.1 Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 19.2 Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 19.3 Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 19.4 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 20.1 Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 20.2 Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 20.3 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.1 Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.2 Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.3 Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.4 Next Generation Drug Conjugates Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.5 Next Generation Drug Conjugates Market for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.6 Next Generation Drug Conjugates Market for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.7 Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 21.8 Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.1 Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.2 Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.3 Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.4 Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.5 Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.6 Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.7 Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.8 Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.9 Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.10 Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.11 Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.12 Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.13 Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.14 Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.15 Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.16 Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.17 Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.18 Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 22.19 Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • Figure 23.1 Next Generation Drug Conjugates Market: Sales Forecast for AMVUTTRA(R) / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02 (USD Million)
  • Figure 23.2 Next Generation Drug Conjugates Market: Sales Forecast for AAA617 / PLUVICTO (USD Million)
  • Figure 23.3 Next Generation Drug Conjugates Market: Sales Forecast for Leqvio(R) / inclisiran (USD Million)
  • Figure 23.4 Next Generation Drug Conjugates Market: Sales Forecast for ARO-APOC3 / Plozasiran / REDEMPLO (USD Million)
  • Figure 23.5 Next Generation Drug Conjugates Market: Sales Forecast for Imetelstat (USD Million)
  • Figure 23.6 Next Generation Drug Conjugates Market: Sales Forecast for Qfitlia(TM) / Fitusiran (USD Million)
  • Figure 23.7 Next Generation Drug Conjugates Market: Sales Forecast for TRYNGOLZA(R) / olezarsen (USD Million)
  • Figure 23.8 Next Generation Drug Conjugates Market: Sales Forecast for WAINZUA / Eplontersen (USD Million)
  • Figure 23.9 Next Generation Drug Conjugates Market: Sales Forecast for Illuccix(R) (68Ga-PSMA-11) (USD Million)
  • Figure 23.10 Next Generation Drug Conjugates Market: Sales Forecast for AAA601 / Lutathera(R) (USD Million)
  • Figure 23.11 Next Generation Drug Conjugates Market: Sales Forecast for Gozellix(R) (USD Million)
  • Figure 23.12 Next Generation Drug Conjugates Market: Sales Forecast for DAWNZERA(TM) / donidalorsen (USD Million)
  • Figure 23.13 Next Generation Drug Conjugates Market: Sales Forecast for OXLUMO(R) / lumasiran (USD Million)
  • Figure 23.14 Next Generation Drug Conjugates Market: Sales Forecast for GIVLAARI(R) / givosiran (USD Million)
  • Figure 23.15 Next Generation Drug Conjugates Market: Sales Forecast for LNTH-2501 / EVG-001 (USD Million)
  • Figure 23.16 Next Generation Drug Conjugates Market: Sales Forecast for Pelacarsen (USD Million)
  • Figure 23.17 Next Generation Drug Conjugates Market: Sales Forecast for Cemdisiran (USD Million)
  • Figure 23.18 Next Generation Drug Conjugates Market: Sales Forecast for SAR-bis PSMA (USD Million)
  • Figure 23.19 Next Generation Drug Conjugates Market: Sales Forecast for RYZ-101 (USD Million)
  • Figure 23.20 Next Generation Drug Conjugates Market: Sales Forecast for ARO-ANG3 / Zodasiran (USD Million)
  • Figure 23.21 Next Generation Drug Conjugates Market: Sales Forecast for Bel-sar / AU-011 (USD Million)
  • Figure 23.22 Next Generation Drug Conjugates Market: Sales Forecast for RBD7022 / QLC7401 (USD Million)